Generic Erivedge Availability
Last updated on Oct 9, 2024.
Erivedge is a brand name of vismodegib, approved by the FDA in the following formulation(s):
ERIVEDGE (vismodegib - capsule;oral)
-
Manufacturer: GENENTECH
Approval date: January 30, 2012
Strength(s): 150MG [RLD]
Has a generic version of Erivedge been approved?
No. There is currently no therapeutically equivalent version of Erivedge available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Erivedge. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,888,364
Patent expiration dates:
- November 11, 2028✓✓
- November 11, 2028
-
Pyridyl inhibitors of hedgehog signalling
Patent 9,278,961
Issued: March 8, 2016
Inventor(s): Gunzner Janet L. & Sutherlin Daniel & Stanley Mark S. & Bao Liang & Castanedo Georgette M. & Lalonde Rebecca L. & Wang Shumei & Reynolds Mark E. & Savage Scott J. & Malesky Kimberly & Dina Michael S. & Koehler Michael F. T.The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:
Patent expiration dates:
- December 15, 2028✓
- December 15, 2028
-
Pyridyl inhibitors of hedgehog signalling
Patent 9,790,183
Issued: October 17, 2017
Inventor(s): Gunzner-Toste Janet L. & Sutherlin Daniel & Stanley Mark S. & Bao Liang & Castanedo Georgette M. & Lalonde Rebecca L. & Wang Shumei & Reynolds Mark E. & Savage Scott J. & Malesky Kimberly & Dina Michael S. & Koehler Michael F. T.
Assignee(s): GENENTECH, INC.The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I:
Patent expiration dates:
- September 2, 2025✓
- September 2, 2025
More about Erivedge (vismodegib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: hedgehog pathway inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
